consequences of glp 1 Mechanisms by which GLP-1 agonists may exert beneficial effects on the Potential mechanisms of weight loss

## **Other relevant codes** Other relevant HCPCS codes related to HCPCS Q5123 (Injection, rituximab-arrx, biosimilar, Riabni 10 mg) include codes for other rituximab biosimilars and related biologic drugs: - Q5115: Injection, rituximab-abbs, biosimilar, 10 mg (Truxima) - Q5119: Injection, rituximab-pvvr, biosimilar, 10 mg (Ruxience) - J9312: Injection, rituximab, 10 mg (reference rituximab drug) - J9311: Injection, rituximab 10 mg and hyaluronidase (combination product) - J3590: Unclassified biologics (used sometimes for unspecified biologics) - Q5122: Injection, pegfilgrastim-apgf, biosimilar, 0.5 mg - Q5124: Injection, ranibizumab-nuna, biosimilar, 0.1 mg Frequently asked questions

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared With Insulin Degludec in Patients With Type 2 Diabetes (SURPASS-3)

GLP-1 agonists like semaglutide and tirzepatide are peptide hormones that activate GLP-1 receptors on pancreatic and gastrointestinal cells

doi: 10.1016/s0167-0115(97)00017-7